LENSAR Inc
NASDAQ:LNSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LENSAR Inc
Total Liabilities & Equity
LENSAR Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LENSAR Inc
NASDAQ:LNSR
|
Total Liabilities & Equity
$71.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$43.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Liabilities & Equity
$13.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$47.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$86.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$20.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
See Also
What is LENSAR Inc's Total Liabilities & Equity?
Total Liabilities & Equity
71.4m
USD
Based on the financial report for Dec 31, 2025, LENSAR Inc's Total Liabilities & Equity amounts to 71.4m USD.
What is LENSAR Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-2%
Over the last year, the Total Liabilities & Equity growth was 8%. The average annual Total Liabilities & Equity growth rates for LENSAR Inc have been 9% over the past three years , -2% over the past five years .
